

Kjetil Bjornevik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3780695/publications.pdf>

Version: 2024-02-01

40
papers

2,587
citations

361413

20
h-index

289244

40
g-index

40
all docs

40
docs citations

40
times ranked

3034
citing authors

#	ARTICLE	IF	CITATIONS
1	Intake of carbohydrates and SFA and risk of CHD in middle-age adults: the Hordaland Health Study (HUSK). <i>Public Health Nutrition</i> , 2022, 25, 634-648.	2.2	4
2	Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women. <i>Multiple Sclerosis Journal</i> , 2022, 28, 121-131.	3.0	2
3	Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. <i>Science</i> , 2022, 375, 296-301.	12.6	892
4	The human gut microbiota in people with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 186-194.	1.7	49
5	Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 133-143.	1.7	12
6	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2021, 31, 388-393.	2.0	8
7	A framework for microbiome science in public health. <i>Nature Medicine</i> , 2021, 27, 766-774.	30.7	47
8	Low vitamin D, but not tobacco use or high BMI, is associated with long-term disability progression in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102801.	2.0	13
9	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, e1466-e1474.	1.1	20
10	Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 58.	9.0	135
11	Ultra-processed food consumption during childhood and asthma in adolescence: Data from the 2004 Pelotas birth cohort study. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 27-37.	2.6	21
12	Big health data and Parkinson's disease epidemiology: Challenges and opportunities. <i>Parkinsonism and Related Disorders</i> , 2020, 71, 58-59.	2.2	2
13	Tenofovir as a treatment option for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102569.	2.0	14
14	Diet pattern and prodromal features of Parkinson disease. <i>Neurology</i> , 2020, 95, e2095-e2108.	1.1	45
15	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 945-955.	3.7	35
16	Prediagnostic plasma polyunsaturated fatty acids and the risk of amyotrophic lateral sclerosis. <i>Neurology</i> , 2020, 94, e811-e819.	1.1	18
17	Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1011-1021.	2.8	5
18	Î±-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2019, 25, 987-993.	3.0	16

#	ARTICLE	IF	CITATIONS
19	Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. <i>Neurology</i> , 2019, 92, 10.1212/WNL.0000000000007401.	1.1	26
20	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1633-1640.	3.0	21
21	Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study. <i>International Journal of Epidemiology</i> , 2019, 48, 1073-1082.	1.9	9
22	Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 194-200.	1.7	11
23	Diabetes is associated with decreased migraine risk: A nationwide cohort study. <i>Cephalalgia</i> , 2018, 38, 1759-1764.	3.9	14
24	Urate and the risk of Parkinson's disease in men and women. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 76-82.	2.2	42
25	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018, 24, 590-603.	3.0	101
26	Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 150-157.	3.0	47
27	Body size and physical exercise, and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 270-278.	3.0	31
28	Neurofilament light chain predicts disease activity in relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e422.	6.0	107
29	Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 92, 10.1212/WNL.0000000000006669.	1.1	5
30	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 869-874.	2.4	10
31	Level of education and multiple sclerosis risk over a 50-year period: Registry-based sibling study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 213-219.	3.0	17
32	Polyunsaturated fatty acids and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1830-1838.	3.0	74
33	Î²2-Adrenoreceptor is a regulator of the Î±-synuclein gene driving risk of Parkinson's disease. <i>Science</i> , 2017, 357, 891-898.	12.6	341
34	Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1018-1024.	3.0	18
35	Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom. <i>Annals of Neurology</i> , 2016, 80, 616-624.	5.3	82
36	Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 104-111.	3.0	35

#	ARTICLE	IF	CITATIONS
37	Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study. Multiple Sclerosis Journal, 2015, 21, 1856-1864.	3.0	58
38	Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study. Multiple Sclerosis Journal, 2015, 21, 388-395.	3.0	90
39	Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes; the EnvIMS Study. Multiple Sclerosis Journal, 2014, 20, 669-674.	3.0	30
40	Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study. Multiple Sclerosis Journal, 2014, 20, 1042-1049.	3.0	80